Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 2
2004 3
2005 2
2006 2
2007 3
2008 2
2009 1
2011 2
2012 1
2013 2
2014 3
2015 3
2016 2
2018 4
2019 5
2020 4
2021 3
2022 3
2023 3
2024 8
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

57 results

Results by year

Filters applied: . Clear all
Page 1
PI3K/mTOR inhibition induces tumour microenvironment remodelling and sensitises pS6high uterine leiomyosarcoma to PD-1 blockade.
De Wispelaere W, Annibali D, Tuyaerts S, Messiaen J, Antoranz A, Shankar G, Dubroja N, Herreros-Pomares A, Baiden-Amissah REM, Orban MP, Delfini M, Berardi E, Van Brussel T, Schepers R, Philips G, Boeckx B, Baietti MF, Congedo L, HoWangYin KY, Bayon E, Van Rompuy AS, Leucci E, Tabruyn SP, Bosisio F, Mazzone M, Lambrechts D, Amant F. De Wispelaere W, et al. Among authors: tuyaerts s. Clin Transl Med. 2024 May;14(5):e1655. doi: 10.1002/ctm2.1655. Clin Transl Med. 2024. PMID: 38711203 Free PMC article.
Editorial: Approaches to Advance Cancer Vaccines to Clinical Utility.
Van Nuffel AMT, Boudousquié C, Tuyaerts S. Van Nuffel AMT, et al. Among authors: tuyaerts s. Front Immunol. 2019 Aug 27;10:2032. doi: 10.3389/fimmu.2019.02032. eCollection 2019. Front Immunol. 2019. PMID: 31507617 Free PMC article. No abstract available.
Trial watch: Dendritic cell (DC)-based immunotherapy for cancer.
Laureano RS, Sprooten J, Vanmeerbeerk I, Borras DM, Govaerts J, Naulaerts S, Berneman ZN, Beuselinck B, Bol KF, Borst J, Coosemans A, Datsi A, Fučíková J, Kinget L, Neyns B, Schreibelt G, Smits E, Sorg RV, Spisek R, Thielemans K, Tuyaerts S, De Vleeschouwer S, de Vries IJM, Xiao Y, Garg AD. Laureano RS, et al. Among authors: tuyaerts s. Oncoimmunology. 2022 Jul 4;11(1):2096363. doi: 10.1080/2162402X.2022.2096363. eCollection 2022. Oncoimmunology. 2022. PMID: 35800158 Free PMC article.
Preclinical evaluation of antigen-sensitive B7-H3-targeting nanobody-based CAR-T cells in glioblastoma cautions for on-target, off-tumor toxicity.
Meeus F, Funeh CN, Awad RM, Zeven K, Autaers D, De Becker A, Van Riet I, Goyvaerts C, Tuyaerts S, Neyns B, Devoogdt N, De Vlaeminck Y, Breckpot K. Meeus F, et al. Among authors: tuyaerts s. J Immunother Cancer. 2024 Nov 19;12(11):e009110. doi: 10.1136/jitc-2024-009110. J Immunother Cancer. 2024. PMID: 39562005 Free PMC article.
Potential Therapeutic Targets in Uterine Sarcomas.
Cuppens T, Tuyaerts S, Amant F. Cuppens T, et al. Among authors: tuyaerts s. Sarcoma. 2015;2015:243298. doi: 10.1155/2015/243298. Epub 2015 Oct 21. Sarcoma. 2015. PMID: 26576131 Free PMC article. Review.
Intracranial administration of anti-PD-1 and anti-CTLA-4 immune checkpoint-blocking monoclonal antibodies in patients with recurrent high-grade glioma.
Duerinck J, Lescrauwaet L, Dirven I, Del'haye J, Stevens L, Geeraerts X, Vaeyens F, Geens W, Brock S, Vanbinst AM, Everaert H, Caljon B, Bruneau M, Lebrun L, Salmon I, Kockx M, Tuyaerts S, Neyns B. Duerinck J, et al. Among authors: tuyaerts s. Neuro Oncol. 2024 Dec 5;26(12):2208-2221. doi: 10.1093/neuonc/noae177. Neuro Oncol. 2024. PMID: 39406392 Clinical Trial.
A randomized phase II clinical trial of stereotactic body radiation therapy (SBRT) and systemic pembrolizumab with or without intratumoral avelumab/ipilimumab plus CD1c (BDCA-1)+/CD141 (BDCA-3)+ myeloid dendritic cells in solid tumors.
Vounckx M, Tijtgat J, Stevens L, Dirven I, Ilsen B, Vandenbroucke F, Raeymaeckers S, Vekens K, Forsyth R, Geeraerts X, Van Riet I, Schwarze JK, Tuyaerts S, Decoster L, De Ridder M, Dufait I, Neyns B. Vounckx M, et al. Among authors: tuyaerts s. Cancer Immunol Immunother. 2024 Jul 2;73(9):167. doi: 10.1007/s00262-024-03751-0. Cancer Immunol Immunother. 2024. PMID: 38954010 Free PMC article. Clinical Trial.
The Controversial Role of PD-1 and Its Ligands in Gynecological Malignancies.
Marinelli O, Annibali D, Aguzzi C, Tuyaerts S, Amant F, Morelli MB, Santoni G, Amantini C, Maggi F, Nabissi M. Marinelli O, et al. Among authors: tuyaerts s. Front Oncol. 2019 Oct 15;9:1073. doi: 10.3389/fonc.2019.01073. eCollection 2019. Front Oncol. 2019. PMID: 31681606 Free PMC article. Review.
An open-label, single-arm, prospective, multi-center, tandem two-stage designed phase II study to evaluate the efficacy of fulvestrant in women with recurrent/metastatic estrogen receptor-positive gynecological malignancies (FUCHSia study).
Trozzi R, Tuyaerts S, Annibali D, Herreros Pomares A, Boog L, Van Dam P, Leunen K, Deroose C, Trum H, Amant F. Trozzi R, et al. Among authors: tuyaerts s. Int J Gynecol Cancer. 2024 Aug 5;34(8):1217-1224. doi: 10.1136/ijgc-2023-005229. Int J Gynecol Cancer. 2024. PMID: 38724237 Clinical Trial.
57 results